Phase II, Multicenter, Open-Label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

Trial Profile

Phase II, Multicenter, Open-Label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Lenvatinib (Primary)
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 May 2016 According to Eisai media release, final analysis results of this trial will be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), in June 2016.
    • 26 Aug 2015 Results (n=59) published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top